Does Insurance Cover GLP-1 Weight-Loss Drugs?

Why there’s no single yes-or-no answer

The most common question people ask about Wegovy, Zepbound, and the rest of the GLP-1 family is also the hardest to answer cleanly: “Will my insurance cover it?” The honest reply is that it depends on two variables that have nothing to do with the drug itself — what kind of plan you have, and what condition it’s being prescribed for.

The same molecule can be covered generously, covered with hurdles, or not covered at all, depending on whether you’re on a large employer plan, an individual marketplace plan, Medicare, or Medicaid — and whether your prescription is written for obesity, type 2 diabetes, cardiovascular risk reduction, or obstructive sleep apnea. A diabetes prescription for semaglutide (Ozempic) is treated very differently by insurers than a weight-loss prescription for the same drug under the Wegovy label, even though the active ingredient is identical.

That “indication split” is the single most important thing to understand before you start. Coverage for GLP-1s used to treat a recognized medical condition other than obesity is widespread and stable. Coverage for GLP-1s used purely for weight management is patchy, shrinking on the commercial side, and historically blocked on the government side. Everything below is organized around that distinction.

Note: This page is about how coverage works — the rules, the paperwork, and the programs. For sticker prices and cash-pay routes, see the dedicated cost pages linked throughout.

Commercial and employer plans

This is where most working-age Americans get their coverage, and it’s also where the picture has shifted most in 2026 — generally toward less access for weight-loss use.

Across the commercial market, the number of people with no coverage at all for weight-loss GLP-1s has climbed sharply. Research tracking these plans found that, entering 2026, tens of millions more people lost commercial coverage for Wegovy and Zepbound than the year before. And among those who do keep coverage, the large majority — over 88% — still have to clear additional requirements before a prescription gets paid.

How coverage varies by employer size

Coverage tracks closely with how big your employer is. Large employers are far more likely to include weight-loss medication as a benefit; small employers rarely do. The rough breakdown looks like this:

• Very large employers (20,000+ workers): the majority cover GLP-1s for weight loss.
• Large employers (5,000+ workers): roughly four in ten cover them.
• Smaller employers (a few hundred workers): only a small minority do.

If you’re on a “Blue Cross” or “UnitedHealthcare” or “Aetna” plan, the insurer’s name tells you almost nothing on its own. Blue Cross Blue Shield, for instance, is a federation of dozens of independent companies, and each designs its own formularies. What ultimately decides your coverage is the specific plan design your employer bought, not the logo on your card.

Self-funded plans and why coverage is shrinking

A large share of US workers are on self-funded employer plans, where the employer pays claims directly and the insurer just administers them. These plans are governed by the federal ERISA law, which does not require employers to cover weight-loss drugs. That gives employers wide latitude to add, restrict, or drop the benefit — and courts have generally sided with that discretion.

Faced with the cost of covering a popular, long-term, expensive class of drugs, many employers have tried step therapy, prior authorization, and lifestyle-program prerequisites, then concluded none of those guardrails slowed spending enough — and dropped weight-loss coverage while keeping diabetes coverage intact. Several insurers also pared back their standard formularies during 2025 and 2026, removing or restricting weight-loss GLP-1s for individual and small-group members.

Prior authorization: what plans typically ask for

If your plan does cover weight-loss GLP-1s, expect a prior authorization (PA). This is the documentation hurdle a provider’s office submits before the plan agrees to pay. Common requirements include:

• A qualifying BMI — usually 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or sleep apnea.
• Documented prior attempts at weight management — often three to six months of diet, lifestyle, or program participation on record. Some plans have raised this to a full six months.
• Step therapy — trying a lower-cost option first (an older anti-obesity drug, for example) before a GLP-1 is approved.
• Formulary tier and quantity limits — even when approved, the drug may sit on a specialty tier with higher cost-sharing.

The practical upshot: coverage often hinges less on whether the drug is “on the list” and more on whether your records satisfy the PA criteria.

Medicare: the statutory wall and the new Bridge

Medicare is a special case because of a decades-old rule. By federal statute, Medicare Part D cannot cover a drug prescribed for weight loss — weight-loss medications are in an excluded category, alongside a handful of others. Changing that would take an act of Congress.

There are two important exceptions to know:

1. Other indications are covered normally. If a GLP-1 is prescribed for an FDA-approved use other than weight loss, Part D can cover it under its usual rules. In practice that means Ozempic and Mounjaro for type 2 diabetes, Wegovy to reduce cardiovascular risk in people with established heart disease, and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. These still run through your plan’s formulary, prior authorization, and cost-sharing — and in 2026, Part D caps your total out-of-pocket drug spending at $2,100 for the year once you reach it.

2. The temporary Medicare GLP-1 Bridge. This is the big 2026 development. Starting July 1, 2026, the CMS-run Medicare GLP-1 Bridge gives eligible Part D members access to specific GLP-1s for obesity — Wegovy, Zepbound, and Foundayo — for a $50 copayment per 30-day supply. Key details:

• You must be enrolled in a Part D plan (standalone or through a Medicare Advantage drug plan), but the Bridge operates outside the normal Part D benefit.
• Eligibility is based on BMI — broadly, 35 or higher on its own, or 27 or higher with additional clinical criteria.
• It’s time-limited. Originally planned to run only through the end of 2026, it has been extended through December 31, 2027, while the longer-term BALANCE Model demonstration was delayed.
• Low-income subsidy (Extra Help) cost-sharing reductions generally can’t be applied to Bridge fills, so the $50 copay is a flat figure for everyone in the program.
• CMS has been releasing operational details — including the prior authorization process — in the run-up to launch.

If you already qualify for coverage through a standard indication (diabetes, CVD, sleep apnea), you keep using your regular Part D benefit for that — the Bridge is specifically the obesity-only pathway.

Medicaid: optional, and getting narrower

Medicaid coverage of GLP-1s splits along the same indication line. Under federal rules, state Medicaid programs must cover GLP-1s for medically accepted FDA-approved indications other than weight loss — so diabetes coverage is effectively required. But covering them for obesity is optional, left to each state.

As of early 2026, only about 13 states covered GLP-1s for obesity, down from 16 the year before — a retreat driven by the cost of coverage and tight state budgets. Some large states tightened access further: California’s Medi-Cal program, for example, removed Wegovy, Zepbound, and Saxenda for weight-loss indications at the start of 2026, while continuing to allow them for specific covered conditions like cardiovascular disease, MASH, or sleep apnea.

If you’re on Medicaid, the realistic expectation is that diabetes and other recognized indications are covered, but obesity coverage depends entirely on your state — and even where it exists, prior authorization and strict criteria usually apply.

Manufacturer savings cards (and why government plans are excluded)

For people with commercial insurance, manufacturer savings cards are often the single biggest lever on out-of-pocket cost.

• A Wegovy savings card can bring eligible commercially insured patients down to as little as $0–$25 per month when the plan covers the drug.
• A Zepbound savings card works similarly, though Eli Lilly tightened the program in 2026 — reducing the maximum monthly benefit, adding a household-income cap, and cutting the lifetime number of fills. Covered patients can still pay as little as $25, while those whose plan doesn’t cover the drug pay a higher self-pay rate through the same card.

Two rules trip people up:

They don’t work with government insurance. Manufacturer copay cards are barred from use with Medicare, Medicaid, TRICARE, or VA coverage. If you have any of those, the card isn’t an option — the Medicare GLP-1 Bridge or a patient-assistance program is the relevant path instead.

They’re not stackable with each other. Manufacturers treat each program as a separate lane, not a pile of discounts to combine. You generally pick one route — commercial insurance plus the savings card, or direct self-pay, or a patient-assistance program — and optimize within it. You can’t, for example, layer a savings card on top of the manufacturer’s already-discounted direct-pay price.

HSA, FSA, and bridging a gap in coverage

If you’re paying out of pocket — whether because you’re uninsured for the drug, in a deductible phase, or paying a specialty-tier copay — pre-tax accounts can help. GLP-1s are generally HSA- and FSA-eligible when prescribed by a licensed provider to treat a diagnosed condition such as obesity or diabetes. The eligibility test is the prescription and medical necessity, not the brand on the box, so the same logic applies whether you’re filling Ozempic, Wegovy, or Zepbound. Using pre-tax dollars effectively discounts the cost by your marginal tax rate.

Some people who lose coverage look at compounded semaglutide or tirzepatide as a cheaper route. That’s a more complicated legal and safety picture than it appears — the regulatory status changed substantially once the official shortages resolved — so it’s worth reading the dedicated explainer before assuming it’s a clean alternative.

If you’re denied — and what’s changing next

A denial isn’t always the end of the road. If a PA is rejected, your provider can usually file an appeal or a formulary exception request with additional documentation, and persistence matters — many initial denials turn on missing paperwork rather than a hard “no.” If your employer offers an optional coverage rider, that can be another route. And if coverage simply isn’t available, the manufacturer self-pay programs and patient-assistance programs exist precisely for that gap.

The landscape is moving quickly. Beyond the Medicare GLP-1 Bridge, manufacturers have announced list-price cuts taking effect in 2027 — Novo Nordisk said it would reduce Wegovy and Ozempic list prices significantly — and Medicare is negotiating prices on some of these drugs for future years. Direct-to-consumer cash programs from both major manufacturers have also reshaped what “no insurance” actually costs. None of this is static, so treat any specific figure here as current as of this page’s update date and verify your own plan’s formulary before you count on it.

The single most useful move, in every scenario, is to call the number on your insurance card and ask three specific questions: Is this drug on my formulary? Is it covered for my diagnosis? And what does the prior authorization require? Those answers — not a general rule — decide what you’ll actually pay.